Cold Storage Product cannot be returned or exchanged. Available at selected pin codes.
TRULICITY 0.75MG contains dulaglutide is Glucagon-like Peptide-1 Agonists (GLP-1 Agonist) which belongs to the class of medications called incretin mimetics. It is used to lower blood sugar (glucose) in adults with type 2 diabetes mellitus and can help to prevent the heart disease. Type 2 diabetes is a condition in which body does not make enough insulin, and the insulin that your body produces does not work as well as it should. When this happens, sugar (glucose) builds up in blood.
GLP-1 makes your pancreas to produce more insulin after you eat and helps in maintaining blood glucose levels in the normal range. It helps the pancreas to release the right amount of insulin when blood sugar levels are high. Insulin helps in moving sugar from the blood into other body tissues where it is used for energy.
Always use this medicine as doctor told you. It is not recommended for the children and adolescents under 18 years of age. It is not recommended for use in people with the severe stomach or intestinal problems. Do not take TRULICITY 0.75MG if you are pregnant or breast feeding, or if you are trying to become pregnant. Consult your doctor for advice. The most common side effects such as nausea, diarrhea, vomiting, decreased appetite, indigestion.
TRULICITY 0.75MG activates GLP-1 receptor, a membrane-bound cell-surface receptor coupled to adenylyl cyclase in the pancreatic beta cells. GLP-1 makes your pancreas to produce more insulin after you eat and helps in maintaining blood glucose levels in the normal range. It helps the pancreas to release the right amount of insulin when blood sugar levels are high. Insulin helps in moving sugar from the blood into other body tissues where it is used for energy.
Always use TRULICITY 0.75MG as doctor told you. It is injected under the skin (subcutaneous injection) of your stomach area (abdomen) or upper leg (thigh). If the injection is given by someone else, they may inject in upper arm. It may be taken with or without food.
Headache:
Apply hot or cold-water bag on your head. Take rest in a quiet and dark room. Drink tea or coffee.
Diarrhea:
Drink lot of fluid, such as water or squash, to avoid dehydration. Do not take any other medicines consulting your doctor.
TRULICITY 0.75MG is not recommended for use in pregnant women unless necessary. Discuss the risks and benefits with your doctor.
TRULICITY 0.75MG is not recommended for use in breastfeeding women unless necessary. Discuss the risks and benefits with your doctor.
If you use TRULICITY 0.75MG in combination with a sulphonylurea or insulin, low blood sugar (hypoglycaemia) may occur which may reduce your ability to concentrate. Please keep this in mind in all situations where you might put yourself and others at the risk.
Consumption of alcohol is not recommended during treatment with this medicine.
TRULICITY 0.75MG should be taken with caution in patients with severe kidney disease. Consult your doctor for advice.
TRULICITY 0.75MG should be taken with caution in patients with severe liver disease. Consult your doctor for advice.
Do not take if you are allergic to the medicine.
Do not use TRULICITY 0.75MG if you:
Talk to your doctor if you are using, have recently used or might use any other medicine.
Drug | : | Dulaglutide |
Pharmacological Category | : | Glucagon-like Peptide-1 Agonists (GLP-1 Agonist) |
Therapeutic Indication | : | Type II Diabetes mellitus |
Dosage Forms | : | Injection |
Store at temperature 2-8°C and keep out of reach of children. Do not freeze.
Can TRULICITY 0.75MG be used in pregnant women?
No. It is not recommended for use in the pregnant women. Consult your doctor before taking.
How long can you stay on TRULICITY 0.75MG?
It may take this medicine up to 5 weeks to start lowering your blood glucose levels but the maximum effect will not be seen for 3-6 months.
What is TRULICITY 0.75MG made of?
It is novel glucagon-like peptide-1 agonist (GLP-1) and biologic drug consisting of the dipeptidyl peptidase-IV-protected GLP-1 analogue covalently linked to human IgG4-Fc heavy chain by a small peptide linker.
1. Celeste B Burness, Lesley J Scott; Dulaglutide: A Review in Type 2 Diabetes; [Published on Dec 2015] https://pubmed.ncbi.nlm.nih.gov/26423061/
2. Eli Lilly and Company; Trulicity (dulaglutide) for the Treatment of Type 2 Diabetes [Published on 2014] https://www.clinicaltrialsarena.com/projects/trulicity-type-2-diabetes/
3. Eli Lilly and Company Indianapolis, IN 46285, USA; U.S. Food & Drug Administration; [Revised on Jan 2017] [Accessed 04 Nov 2020] https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125469s007s008lbl.pdf
4. Eli Lilly Italia S.p.A.,Via Gramsci 731/733, 50019, Sesto Fiorentino, Firenze (FI), Italy; Electronic Medicines Compendium (EMC); [Revised on Oct 2019] [Accessed 04 Nov 2020] https://www.medicines.org.uk/emc/files/pil.3634.pdf
The contents of this website are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website.